Latest News and Press Releases

This Luxembourg tender win marks Tilray Medical's further expansion through Europe.

Tilray Medical announced the launch of its first commercial German grown medical cannabis flowers from its Aphria RX GmbH (“Aphria RX”) facility.

This trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from negative chemotherapy-induced side effects.

TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company, announced the launch of new Charlotte's...

Tilray's EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription.

LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the...

Tilray-led scientific publication examines the real-world impact of medical cannabis use on patients over the age of 50.

Tilray Medical announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada.

Tilray Medical has received approval for the first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20, in Portugal.

Tilray is bullish on the positive paradigm shift that the new German drug policy creates for the future of cannabis in Europe.